Preclinical Evidence is a recurring topic in our peptide coverage. This hub collects every article tagged Preclinical Evidence, newest first, each evidence-graded and tied to real, verifiable sources.
A clinical monograph on MGF (IGF-1Ec) — the mechanosensitive IGF-1 splice variant marketed for muscle repair and satellite-cell activation. Compelling rodent mechanism, contested preclinical data, zero human trials, and an unsettled 2026 legal and anti-doping status.
A clinical monograph on LL-37 — the only human cathelicidin antimicrobial peptide. Small topical wound-healing RCTs (grade B), strong preclinical mechanism, and a sharply double-edged immune profile.
A clinical monograph on Livagen (KEDA; Lys-Glu-Asp-Ala) — a Khavinson 'bioregulator' tetrapeptide proposed to decondense aged chromatin and protect the liver. Single-lab preclinical signals only, no human trials.
A clinical monograph on Cardiogen (AEDR; H-Ala-Glu-Asp-Arg-OH), the cardiac-targeted Khavinson bioregulator tetrapeptide. Coherent in-vitro mechanism, zero human trials, and an unapproved 2026 legal status.
A clinical monograph on KPV — the anti-inflammatory tripeptide fragment of alpha-MSH. Deep rodent and cell-culture data for gut and skin inflammation, zero human trials, and an unsettled 2026 legal status.
A clinical monograph on IGF-1 LR3 (Long R3 IGF-1) — the IGFBP-evading, long-acting IGF-1 receptor agonist sold as a lab reagent. Real animal anabolic signal, zero human trials, and serious hypoglycemia and cancer-promotion concerns.
A clinical monograph on des(1-3)IGF-I — the truncated, IGFBP-evading IGF-1 analogue marketed for localized muscle growth. Potent in rodents, unproven in humans, and WADA-banned at all times.
A clinical monograph on humanin — the first mitochondrial-derived peptide. Deep preclinical cytoprotection data, intriguing human biomarker correlations, zero interventional human trials, and a real tumor-promotion caveat.
A clinical monograph on HGH Fragment 176-191 — the C-terminal 'lipolytic tail' of growth hormone sold as a fat-loss peptide. No human RCTs, an antilipogenic animal mechanism, and a closely related analogue (AOD-9604) that failed its pivotal obesity trial.
A clinical monograph on glycyl-L-glutamine (Gly-Gln) — the stable glutamine-carrier dipeptide of parenteral nutrition that is also the endogenous β-endorphin-(30–31) neuropeptide. Real human-trial evidence for IV glutamine delivery; cardiometabolic claims are preclinical only.
A clinical monograph on SS-20 — the Szeto-Schiller mitochondria-targeting tetrapeptide that protects mitochondria without antioxidant chemistry. Deep preclinical data, no human trials, and unapproved research-only status in 2026.
A clinical monograph on follistatin and FS-344 — the activin-myostatin trap marketed for muscle growth. Real human signal exists only as small gene-therapy trials; the injectable peptide has no validated efficacy.
A clinical monograph on FGL (FGLL) — the NCAM-derived FGFR1 agonist peptide marketed for memory and neuroprotection. Deep rodent data, one single-dose human safety study, and zero efficacy proof in people.
A clinical monograph on epitalon (epithalon, AEDG) — the synthetic pineal tetrapeptide marketed as a telomerase-activating geroprotector. Real circadian and cell-culture signals, no Western RCT, and a 2026 FDA inflection point.
A clinical monograph on Pinealon (Glu-Asp-Arg / EDR), the Khavinson ultrashort neuroprotective tripeptide. Reproducible preclinical antioxidant data, no human RCT, and an unapproved 2026 legal status.
A clinical monograph on dihexa — the angiotensin IV-derived nootropic peptide promoted for cognition. Its evidence is preclinical only, its foundational mechanism papers were retracted for fraud, and its clinical prodrug failed an Alzheimer's trial.
A clinical monograph on davalintide (AC2307) — Amylin Pharmaceuticals' second-generation amylin-mimetic peptide. Robust rodent fat-loss data, one unreported Phase 2 trial, and a program discontinued in 2010.
A clinical monograph on Cortagen (Ala-Glu-Asp-Pro) — the Khavinson-program 'cytogen' tetrapeptide marketed for nerve repair and neuroprotection. One intriguing rat nerve-regeneration signal, no human RCTs, and an unapproved-research-chemical legal status.
A clinical monograph on CJC-1295 without DAC (Mod GRF 1-29) — the short-acting, pulse-preserving GHRH analog. Solid preclinical pharmacology, no human RCT of the no-DAC molecule, and an unsettled 2026 legal status.
A clinical monograph on Chonluten — the Russian "Khavinson" bronchial bioregulator sold as the tripeptide Glu-Asp-Gly (EDG). Single-lab in-vitro data on a related peptide, no human RCT, and an unapproved 2026 legal status.
Preclinical Evidence is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged Preclinical Evidence, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.